AtriCure Reports Strong Q4 & Full-Year 2025 Results, Guides for Positive 2026 Net Income

summarizeSummary

AtriCure, Inc. finalized strong Q4 and full-year 2025 financial results, reporting significant revenue growth and a return to profitability in Q4, while also issuing positive 2026 guidance including projected positive net income.

check_boxKey Events

• Strong Q4 2025 Performance

  Reported worldwide revenue of $140.5 million, a 13.1% increase year-over-year, with net income of $1.8 million and adjusted EBITDA of $19.9 million.

• Solid Full-Year 2025 Results

  Achieved worldwide revenue of $534.5 million, up 14.9% year-over-year, significantly reducing net loss to $11.4 million and nearly doubling adjusted EBITDA to $61.8 million.

• Positive 2026 Financial Guidance

  Projected full-year 2026 revenue between $600 million and $610 million (12% to 14% growth), with adjusted EBITDA of $80 million to $82 million, and positive net income.

• Operational Momentum

  Growth was driven by expanding use of new products like cryoSPHERE MAX and AtriClip FLEX-Mini, and continued adoption of the EnCompass clamp.

auto_awesomeAnalysis

AtriCure, Inc. reported robust financial results for the fourth quarter and full-year 2025, confirming the strong preliminary figures announced on January 12, 2026. The company achieved significant revenue growth and a notable improvement in profitability, moving from a net loss in 2024 to positive net income in Q4 2025. Furthermore, management provided optimistic guidance for full-year 2026, projecting continued revenue growth and, critically, positive net income, signaling a strong operational turnaround and a clear path to sustained profitability. This performance, driven by expanding product adoption, positions the company favorably for future value creation.